High rate of depression in patients with chronic hepatitis C / Taxa elevada de depressão em pacientes com hepatite C crônica

Objetivos: descrever a frequência de depressão em pacientes com hepatite C (HCV) e relacionar com as variáveis biológicas e função hepática. Métodos: estudo transversal, descritivo, de abordagem quantitativa, que avaliou a depressão utilizando os critérios do Manual de diagnóstico e estatístico de transtornos mentais (DSM-V) e a associação com as variáveis biológicas e de função hepática em 85 pacientes com HCV crônica indicados para a terapia antiviral de ação direta (DAA) entre maio de 2018 e 2019. Resultados: detectou-se depressão em 47,1% dos pacientes, predominantemente depressão leve (95%). Entretanto a depressão ocorreu de forma independente das características biológicas, como sexo, idade, escolaridade, comorbidades associadas e da função hepática, como grau de fibrose e genótipo viral. Conclusões: a frequência de depressão foi alta em pacientes com HCV e não teve relação estatística com as características biológicas e função hepática, sugerindo a busca ativa da depressão como estratégia na condução destes pacientes.

Download Full-text

The Effects of Interferon and Ribavirin in Chronic Hepatite C

Revista de Chimie ◽

10.37358/rc.17.9.5844 ◽

2017 ◽

Vol 68 (9) ◽

pp. 2147-2150

Author(s):

Liliana Coldea ◽

Florin Grosu ◽

Alina Liliana Pintea ◽

Sebastian Ioan Cernusca Mitariu ◽

Nicolae Grigore ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Antiviral Treatment ◽

Public Health Problem ◽

Complete Response ◽

Extrahepatic Manifestations ◽

Hépatite C ◽

Response Versus

The chronic hepatitis C is a frequently problem in worldwide, the number of infected individuals is high and go on, getting a public health problem [1]. In Romania there are nearly 1 million persons infected with hepatitis C virus, the scope of spreading is related with specific risk factors. An important number of infection with hepatitis C virus present simultaneous extrahepatic manifestations proved to be alone manifestation tracing; its important for diagnosis and treatment. We analyzed the effects of interferon and ribavirin in chronic hepatitis C in General C.F. Hospital Sibiu, between 2008 � 2012. The association between infection with hepatitis C virus and extrahepatic manifestations is important to be recognized for adequate diagnosis tests. By comparing the results of therapy in patients with hepatic and extrahepatic manifestations, the study found that 30 patients (58.83 %) with liver manifestations had an incomplete response versus 10 patients (26.32 %) with extrahepatic manifestations; 11 patients (21.54 %) with hepatic manifestations had a complete response versus 3 patients (7.89 %) with extrahepatic manifestations; and 10 patients (19.63 %) with hepatic manifestations did not respond to treatment versus 25 patients (65.79 %) with extrahepatic manifestations. Analyzing the results of antiviral therapy in patients with hepatic manifestations and those with extrahepatic manifestations, antiviral treatment appears to be more advantageous in cases with only hepatic manifestations.

Download Full-text

Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C

International Journal of Molecular Sciences ◽

10.3390/ijms21124517 ◽

2020 ◽

Vol 21 (12) ◽

pp. 4517

Author(s):

Kazuya Takemura ◽

Etsuko Takizawa ◽

Akihiro Tamori ◽

Mika Nakamae ◽

Hiroshi Kubota ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Liver Fibrosis ◽

Chronic Hepatitis C ◽

Antiviral Treatment ◽

Sustained Viral Response ◽

Post Treatment ◽

High Rate ◽

Fibrosis Marker

Patients with chronic hepatitis C virus (HCV) develop hepatocellular carcinoma (HCC) regardless of achieving a sustained viral response (SVR). Because advanced liver fibrosis is a powerful risk factor for HCC, we analyzed the association between autotaxin (ATX), a liver fibrosis marker, and post-SVR HCC development within 3 years after antiviral treatment. We included 670 patients with HCV who received direct-acting antivirals, achieved SVR and were followed up for at least 6 months (270 of them were followed up for 3 years or more). We measured serum ATX levels before treatment and 12/24 weeks after treatment. The diagnosis of HCC was based on imaging modalities, such as dynamic computed tomography and dynamic magnetic resonance imaging and/or liver biopsy. The present study revealed that high levels of serum ATX predicted post-SVR HCC development (area under the receiver operating characteristic: 0.70–0.76). However, Wisteria floribunda agglutinin positive Mac-2 binding protein (M2BPGi), another liver fibrosis marker, was a more useful predictive marker especially post-treatment according to a multivariate analysis. Patients with a high rate of ATX reduction before and after antiviral treatment did not develop HCC regardless of high pretreatment ATX levels. In conclusion, post-treatment M2BPGi level and the combination of pretreatment ATX levels and rate of ATX reduction were useful predictive markers for post-SVR HCC development in patients with chronic HCV infection.

Download Full-text

Chronic hepatitis C as an adverse prognostic factor in myelodysplastic syndromes.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.e18557 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. e18557-e18557

Author(s):

Santiago Thibaud ◽

Justin D. Kaner ◽

Aditi Shastri ◽

Anjali Budhathoki ◽

Ashwin Sridharan ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Myelodysplastic Syndromes ◽

Univariate Analysis ◽

Hematologic Malignancies ◽

Idh1 Mutation ◽

Hcv Infection ◽

High Rate ◽

Female Ratio

e18557 Background: Chronic hepatitis C virus (HCV) infection has been associated with hematologic malignancies such as B-cell non-Hodgkin lymphoma. In contrast, there is very little known about the relationship between HCV and myeloid malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). To determine the effect of HCV on MDS/AML clinical outcomes we conducted a retrospective analysis in a large inner city cohort of patients (pts) Methods: 478 pts with MDS and MDS-transformed AML were identified between 1997 and 2016; 13 pts were HCV-positive (HCV+/MDS) and 465 were HCV-negative (HCV-/MDS). Demographics, hematologic parameters, cytogenetics, IPSS-R scores and molecular profiles were compared for both groups (grp). Survival (surv) analysis was done using the Kaplan-Meier method Results: HCV+/MDS had significantly worse surv than HCV-/MDS pts on univariate analysis (UA) (median surv 16 vs 52 months, HR 2.8, 95% CI 1.4-5.5, p < 0.01). Difference remained strongly significant after exclusion of HIV-coinfected pts (HR 2.7, p = 0.02) and pts w/ AML on presentation (HR 3.1, p < 0.01). Cytopenias were worse in HCV+/MDS (mean Hgb level 8.2 vs 9.4 g/dl, p = 0.04; mean plt count 64 vs 139 103/µL, p = 0.03). Average IPSS-R score was higher in HCV+/MDS pts (5.5 vs 3.8, p = 0.02). IDH1 mutation was more prevalent in HCV+/MDS (25% vs 2%, p < 0.01). Differences in age between HCV+/MDS and HCV-/MDS were non-significant (mean 64 vs 69 respectively, p = 0.2). Male-to-female ratio was higher in HCV+/MDS but difference was non-significant (2.3 vs 0.9, p = 0.2). Interestingly, high HCV viral load and cirrhosis did not correlate with poor surv in the HCV+/MDS grp, suggesting deleterious effect occurs even in early stages of HCV infection. Conclusions: Our analysis suggests that chronic HCV infection strongly correlates with worse surv in UA and is associated with lower blood counts and higher IPSS-R scores at the time of diagnosis of MDS. We observed a high rate of MDS refractory to standard therapies and speculate that HCV may affect biology of the disease. Larger studies are warranted to determine the effect of HCV on surv in this population and to provide a rationale for trials of anti-HCV drugs concomitantly with MDS Tx.

Download Full-text

Considerations on Direct Antiviral Agent Therapy in Patients Having Chronic Hepatitis C from Constanta County

Acta Medica Marisiensis ◽

10.2478/amma-2014-0043 ◽

2014 ◽

Vol 60 (5) ◽

pp. 204-206 ◽

Cited By ~ 1

Author(s):

Angelica Stavar ◽

Irina-Magdalena Dumitru ◽

S Rugina

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Triple Therapy ◽

Chronic Hepatitis C ◽

Standard Therapy ◽

Adverse Reactions ◽

Standard Treatment ◽

Direct Action ◽

High Rate ◽

Number Of Patients

Abstract Introduction: Direct-acting antiviral agents (DAA) have a direct action in chronic hepatitis C, their addition to the standard therapy with interferon alfa2 (IFN) and ribavirin (RBV) significantly improving the sustained virologic response (SVR) in this disease. Objective: The study analyses the results of triple therapy inclduign DAA in terms of tolerability and efficiency. Material and method: We selected a lot of 24 patients who concluded the DAA administration period, being in the period of finalization of standard therapy at the time of the study. In all the patients clinical and paraclinical assesment was performed including laboratory tests, fibroscan, echography, etc. Results: The duration of the therapy consisting in association of DAA to the standard treatment was 3 months and led to a remarkable result represented by a high rate of negativation of viremia (83.3%). Among the adverse reactions recorded, the most important were: anemia 17 patients (70.8%), leucopenia 10 patients (41.6%), thrombocitopenia 14 patients (58.3%), hyperbilirubinemia 3 patients (12,5%); hyperuricemia 8 patients (33,3%), hypocalcemia 4 patients (16.6%), loss of weight 4 patients (16,6%), anal pruritus (16,6%); among the 24 patients, 2% did not exhibit any adverse reactions. Conclusions: Despite of the various adverse reactions recorded, the triple therapy consisting in DAA added to the standard treatment proves its utility, and the high rates of sustained viral reaction justifies its utilization. It is necessary to increase the number of patients who benefit from the advantages of triple therapy, which, after becoming larger available, could become a new standard therapy in patients with viral chronic hepatitis.

Download Full-text

Atorvastatin in Combination with Pegylated Interferon and Ribavirin Provided High Rate of Sustained Virological Response in Patients with Genotype 3 Hepatitis C Virus

Open Access Macedonian Journal of Medical Sciences ◽

10.3889/oamjms.2019.459 ◽

2019 ◽

Vol 7 (10) ◽

pp. 1641-1648 ◽

Cited By ~ 1

Author(s):

Beti Todorovska ◽

Viktorija Caloska-Ivanova ◽

Magdalena Dimitrova-Genadieva ◽

Meri Trajkovska ◽

Rozalinda Popova-Jovanovska ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Combination Therapy ◽

Antiviral Therapy ◽

Chronic Hepatitis C ◽

Pegylated Interferon ◽

High Rate ◽

Genotype 3 ◽

Pegylated Interferon Alpha

BACKGROUND: Chronic hepatitis C virus infection represents a more frequent cause of liver cirrhosis and hepatocellular carcinoma. Statins, inhibit HCV replication in vitro, enhance the antiviral effect of the already known antiviral drugs and reduce their resistance. AIM: To determine the impact of additional therapy (treatment with Atorvastatin 20 mg) to the standard antiviral therapy (pegylated interferon alpha-peg-IFN α and ribavirin) on achieving sustained virological response (SVR). MATERIAL AND METHODS: In the study which is comparative, open-label, prospective-retrospective, 70 patients diagnosed with chronic hepatitis C virus infection who met criteria for treatment with standard antiviral therapy combined with anti-lipemic therapy (Atorvastatin 20 mg) were included. Patients in the study were divided into two groups: one group of 35 patients receiving combination therapy (Atorvastatin + peg-IFN α + Ribavirin) and another group of 35 patients received only standard antiviral therapy. Those parameters were followed in all patients: genotyping, quantification of the virus, histological assessment of liver inflammation and fibrosis degree (before starting treatment), the presence of steatosis, laboratory analysis: hematology, liver, lipid and carbohydrate status, insulin blood level (the calculation of HOMA-IR) and body mass index (BMI) calculation. The overall treatment of the patients depends from the virus genotype, thus, patients with genotype 1 and 4 received 48 weeks standard antiviral therapy, but patients with genotypes 2 and 3 received 24 weeks of antiviral therapy. SVR was considered an undetectable level of HCV RNA levels 24 weeks after completion of antiviral therapy. The results were statistically analysed, and all results for p < 0.05 were considered statistically significant. RESULTS: Combination therapy leads to a slightly higher percentage of SVR (85.71%) in patients with chronic hepatitis C versus standard therapy (74.29%), but in a group of patients with genotype 3 this rate of SVR amounting to 95.83%. Combination therapy leads to significant improvement of lipid and glucose status after treatment, and in terms of side effects, there was no appearance of serious adverse events that would be a reason for discontinuation of the therapy. CONCLUSION: Combination therapy Atorvastatin + pegylated interferon alpha + Ribavirin leads to high rate of SVR of 95.83% in patients with chronic hepatitis C, genotype 3. Statins can be used safely in patients with chronic hepatitis C.

Download Full-text

High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study

Journal of Gastroenterology ◽

10.1007/s005350200119 ◽

2002 ◽

Vol 37 (9) ◽

pp. 732-736 ◽

Cited By ~ 9

Author(s):

Luiz Caetano da Silva ◽

Leda Bassit ◽

Suzane Kioko Ono-Nita ◽

João Renato Rebello Pinho ◽

Ana Nishiya ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Pilot Study ◽

Chronic Hepatitis C ◽

Sustained Response ◽

High Rate ◽

Alpha Interferon ◽

Consensus Interferon ◽

Chronic Hepatitis C Patients

Download Full-text

Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy

International Journal of Molecular Sciences ◽

10.3390/ijms20010049 ◽

2018 ◽

Vol 20 (1) ◽

pp. 49 ◽

Cited By ~ 10

Author(s):

Rosanna Villani ◽

Gianluigi Vendemiale ◽

Gaetano Serviddio

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Molecular Mechanisms ◽

High Rate ◽

Direct Acting Antiviral ◽

High Incidence ◽

Impaired Immune Response ◽

Direct Acting ◽

Hcc Recurrence

Chronic hepatitis C is associated with a high risk of developing hepatocellular carcinoma (HCC) because of a direct effect of the Hepatitis C Virus (HCV) proteins and an indirect oncogenic effect of chronic inflammation and impaired immune response. The treatment of chronic hepatitis C markedly reduces all-cause mortality; in fact, interferon-based treatment has shown a reduction of HCC incidence of more than 70%. The recent introduction of the highly effective direct-acting antivirals (DAAs) has completely changed the scenario of chronic hepatitis C (CHC) with rates of HCV cure over 90%. However, an unexpectedly high incidence of HCC recurrence was observed in patients after DAA treatment (27% versus 0.4–2% in patients who received interferon treatment). The mechanism that underlies the high rate of tumor relapse is currently unknown and is one of the main issues in hepatology. We reviewed the possible mechanisms involved in HCC recurrence after DAA treatment.

Download Full-text

High rate of long-term virological response after a 1-year course of interferon ± ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial

Liver International ◽

10.1034/j.1600-0676.2003.00836.x ◽

2003 ◽

Vol 23 (4) ◽

pp. 255-261 ◽

Cited By ~ 5

Author(s):

Eveline J Boucher ◽

Sylvie Jacquelinet ◽

Valérie Canva ◽

Bruno Turlin ◽

Christian Jacquelinet ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Randomized Trial ◽

Chronic Hepatitis C ◽

Virological Response ◽

High Rate

Download Full-text

Sociodemographic and clinical characterization of patients with chronic hepatitis C

Enfermería Global ◽

10.6018/eglobal.18.3.316971 ◽

2019 ◽

Vol 18 (3) ◽

pp. 157-194

Author(s):

Juliana Mayara da Silva Leite ◽

Jéssica de Oliveira Inácio ◽

Raissa Silva De Melo Monteiro ◽

Cristiane da Câmara Marques ◽

Vanessa Pinheiro Barreto ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Hepatitis B ◽

Chronic Hepatitis C ◽

Hépatite C ◽

Cross Sectional ◽

Multiprofessional Team ◽

Reference Hospital ◽

Discovery Time

Objetivo: Describir la caracterización sociodemográfica y clínica de los pacientes portadores de hepatitis C crónica acompañados en el ambulatorio de un hospital de referencia en infectología. Método: Estudio transversal, descriptivo, cuantitativo, con usuarios portadores de hepatitis C crónica asistidos en el ambulatorio de un hospital de referencia durante noviembre de 2015 a abril de 2016 con una muestra de 47 usuarios. Resultados: Los participantes son de sexo masculino (76,6%) con rango de edad superior a 57 años (57,5%), pardo (38,3%), casado (55,3%), con grado de escolaridad (31,9%), y residente en la capital (61,7%), con tiempo de descubrimiento de hasta 6 años (68,1%), desconociendo la forma de contaminación (57,5%), inmunizado contra la hepatitis B (65,9%), realizando tratamiento medicamentoso (85,1%) con Ribavirina (55,6%); Y el 70,2% presentó efectos adversos. Conclusión: La caracterización sociodemográfica y clínica auxilian en la práctica clínica del equipo multiprofesional con los portadores de hepatitis C crónica. Objective: To describe the sociodemographic and clinical characterization of patients with chronic hepatitis C followed at the outpatient clinic of a reference hospital in infectology.Method: A cross-sectional, descriptive, quantitative study with chronic hepatitis C patients attended at a referral hospital during November 2015 to April 2016 with a sample of 47 users. Results: The participants were male (76.6%), 57 years old (57.5%), brown (38.3%), married (55.3%), (61.7%), with a discovery time of up to 6 years (68.1%), not knowing the form of contamination (57.5%), immunized against hepatitis B (65.9%), undergoing drug therapy (85.1%) with Ribavirin (55.6%); And 70.2% had adverse effects. Conclusion: Sociodemographic and clinical characterization assist the clinical practice of the multiprofessional team with patients with chronic hepatitis C Objetivo: Descrever a caracterização sociodemográfica e clínica dos pacientes portadores de hepatite C crônica acompanhados no ambulatório de um hospital referência em infectologia. Método: Estudo transversal, descritivo, quantitativo, com usuários portadores de hepatite C crônica assistidos no ambulatório de um hospital referência durante Novembro 2015 a Abril de 2016 com uma amostra de 47 usuários. Resultados: Os participantes encontram-se no sexo masculino (76,6%) com faixa etária acima de 57 anos (57,5%), pardo (38,3%), casado (55,3%), com grau de escolaridade fundamental incompleto (31,9%), e residente na capital (61,7%), com tempo de descoberta de até 6 anos (68,1%), desconhecendo a forma de contaminação (57,5%), realizando tratamento medicamentoso (85,1%) com Ribavirina (55,6%); e 70,2% apresentaram efeitos adversos. Conclusões: A caracterização sociodemográfica e clínica auxiliam na prática clínica da equipe multiprofissional com os portadores de hepatite C crônica.

Download Full-text